Analyzing gut bacteria in pancreatic cancer surgery patients
Official title: Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer (MIcRobiome Analysis in Patients UnderGoing PancrEatico-duodenectomy for Pancreatic Cancer MIRAGE Study)
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06800469 · Data updated 2026-11-12
This study is trying to see if certain gut bacteria in patients having surgery for pancreatic cancer can help predict complications after the operation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, BO) |
| Status | Recruiting |
| Started | July 11, 2022 |
| Main results expected | July 1, 2025 |
| Study ends | July 1, 2025 |
| Registry record updated | January 30, 2025 |
| Trial ID | NCT06800469 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older diagnosed with resectable pancreatic adenocarcinoma who are eligible for upfront surgical treatment.
✕Probably not a fit
Patients who are pregnant or lactating will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the relationship between gut microbiota and postoperative complications in patients undergoing duodenocephalopancreasectomy for pancreatic cancer. It aims to identify specific bacterial species that may be associated with increased risks of complications such as pancreatic and biliary fistulas. By analyzing the gut microbiota, the study seeks to provide insights that could improve surgical outcomes and reduce morbidity. The research is based on preliminary findings from other surgical fields suggesting that gut bacteria may influence recovery and complication rates.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical outcomes and reduced complications for patients undergoing surgery for pancreatic cancer.
How similar studies have gone: Preliminary studies in colorectal surgery have shown success in linking gut microbiota to surgical outcomes, suggesting potential for this approach in pancreatic cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Diagnosis of resectable pancreatic adenocarcinoma with indication for "upfront" surgical treatment * ASA (American Society of Anesthesiology) score \< 4 * Obtaining informed consent Exclusion Criteria: \- Pregnant or lactating women
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bo, Italy Recruiting
Study contacts
- Principal investigator: Ricci Claudio, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Claudio Ricci, MD
- Email: claudio.ricci@aosp.bo.it
- Phone: +39 051 214 3928
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BEFAST: Total Body PET/CT with Ga-68 FAPI for Better Imaging in Cancer
This study tests whether Ga-68 FAPI-46 Total Body PET/CT can better detect cancer spread and provide fast, clear images for adults with pancreatic or gastroesophageal cancer.
-
Chronic Stress and Pancreatic Cancer Outcomes in People with Pancreatic Cancer
This study tests whether ongoing psychological stress affects how pancreatic cancer behaves and responds to treatment in adults.
-
Prehab to get stronger before pancreatic cancer surgery
This project will test whether adults with pancreatic cancer can follow a combined exercise, nutrition, and symptom-management program during chemotherapy to improve fitness and recovery before surgery.
-
Surufatinib with Gemcitabine and Nab-paclitaxel as Neoadjuvant Therapy for High-Risk or Borderline Resectable Pancreatic Cancer
This trial tests whether adding surufatinib to gemcitabine and nab-paclitaxel before surgery helps adults with high-risk resectable or borderline resectable pancreatic cancer.
-
Peptamen 1.6 versus Resource HP/HC for nutrition after cephalic pancreaticoduodenectomy
This tests whether Peptamen 1.6, a hydrolysed whey protein oral supplement, helps malnourished or at-risk adults recover better than a standard high-protein/high-calorie formula after cephalic pancreaticoduodenectomy for pancreatic or periampullary cancer.
-
Using deep learning and Raman spectroscopy for early cancer diagnosis
This study is trying to see if a new deep learning tool using blood samples can help spot early signs of different types of cancer, like colorectal and gastric cancers, in both healthy people and those already diagnosed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.